Oxidative stress-related proteins in a Conn's adenoma tissue. Relevance for aldosterone's prooxidative and proinflammatory activity

Journal of Endocrinological Investigation

Volumn 33, Issue 1, 2010, Pages 48-53

  Calo L A ^a   Pagnin, E ^a   Davis, P A ^b   Armanini, D ^a   Mormino, P ^a   Rossi, G P ^a   Pessina, A C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aldosterone; Conn's adenoma; Mineralocorticoid receptors; Oxidative stress; TGF

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; HEME OXYGENASE 1; HYDROCORTISONE; IRBESARTAN; MINERALOCORTICOID RECEPTOR; NEBIVOLOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRANSFORMING GROWTH FACTOR BETA;

ADENOMA; ADRENALECTOMY; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERTENSION; INFLAMMATION; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLANDS; ADRENOCORTICAL ADENOMA; ADULT; ALDOSTERONE; FEMALE; GENE EXPRESSION; HEME OXYGENASE-1; HUMANS; HYPERALDOSTERONISM; NADPH OXIDASE; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, MINERALOCORTICOID; TRANSFORMING GROWTH FACTOR BETA;

EID: 77950531642     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/bf03346549     Document Type: Article

References (34)

1. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003, 91 : 7A-11A.
2. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertension 2000, 18: 655-673
3. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease. A unifying hypothesis. Hypertension 2001, 37: 1047-1052
4. Mehta PK, Griendling KK. Angiotensin II cell signaling, physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007, 92: C82-C97.
5. Fritsch Neves M, Schiffrin EL. Aldosterone: A risk factor for vascular disease. Curr Hypertens Rep 2003, 5: 59-65.
6. Gekle M, Mildenberger S, Freudinger R, Grossmann C. Altered collagen homeostasis in human aortic smooth muscle cells (HAoSMCs) induced by aldosterone. Pflugers Arch 2007, 454: 403-413
7. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor beta 1 in renal fibrosis of rats. Hypertension 2000, 35: 1078-1084
8. Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI-1 : implications for renal injury. J Nephrol 2002, 15: 230-235
9. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin l/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101: 594-597
10. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress in angiotensin II-infused rats. Hypertension 2002, 40: 504-510
11. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal disfunction: a paradigm shift. J Hypertension 2001, 19: 829-842
12. Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC. The endothelin- aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol 2001, 38 (Suppl 2): S49-52.
13. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105: 2212-2216
14. Pu Q, Neves MF Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003, 42: 49-55.
15. Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003, 41: 955-963
16. Calo LA, Zaghetto F, Pagnin E, et al. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab 2004, 89: 1973-1976.
17. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Circ Res 2000, 86: 494-501.
18. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997, 37: 517-554
19. Nath KA, Grande J, Croatt A, Haugen J, Kim Y, Rosenberg ME. Redox regulation of renal DNA synthesis, transforming growth factor-beta-1 and collagen gene expression. Kidney Int 1998, 53: 367-381
20. Silacci P, Hayoz D. Oxidative stress as the triggering event for vascular remodelling. Nephrol Dial Transplant 1998, 13: 1343-1346
21. Calò LA, Pagnin E, Davis PA, Sartori M and Semplicini A. Oxidative stress-related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrol Dial Transplant 2003, 18: 1518-1525
22. Calò LA, Naso A, Carraro G et al. Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol Dial Transplant 2007, 22: 1413-1419
23. Azhar S, Cao L, Reaven E. Alteration of the adrenal antioxidant defense system during aging in rats. J Clin Invest 1995, 96: 1414-1424
24. Homsby PJ. Steroid and xenobiotic effects on the adrenal cortex: mediation by oxidative and other mechanisms. Free Radic Biol Med 1989, 6: 103-115
25. Eitzman DT, McCoy RD, Zheng X, et al. Bleomicin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996, 97: 232-237
26. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999, 96: 319-328
27. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002, 14: 681-685
28. Lijnen PJ, Petrov W, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-β1. Mol Gen Metab 2000, 71: 418-435
29. Klahr S. Progression of chronic renal disease. Heart Dis 2001, 3: 205-209
30. Diah S, Zhang GX, Nagai Y, et al. Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. Exp Cell Res 2008, 314: 3654-3662
31. Takeda K, Ichiki T, Tokunou T, et al. Critical role of Rho-kinase and MEK-ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vase Biol 2001, 21: 868-873
32. Immenschuh S and Ramadori G. Gene regulation of heme oxygenases as a therapeutic target. Biochem Pharmacol 2000, 60: 1121-1128
33. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283: H1802-10.
34. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002, 143: 4828-4836